Clinical Trial Update: ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ESK981 in combination with Nivolumab for metastatic castration-resistant prostate cancer was terminated; results were posted on 2024-07…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• ESK981
• nivolumab (nivolumab)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2024-07-16